...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Have a great Sunday, especially those of you like me that are celebrating Orthodox Easter ... As well as those of you who are also like me and mourning another Maple Leafs Game 7 exit ... Ugggh!

Sincerely,

George et al

Message: Re: https://scr.zacks.co...
7
May 04, 2020 10:59AM
5
May 04, 2020 11:02AM

Nice find Fuzzy. Glad to see Zenith getting some attention. At the same time, I no longer see Resverlogix on the list of covered companies for Zacks/SCR. John Vandermosten and Zacks were the most frequent to update their Resverlogix analysis. 

BDAZ

4
May 05, 2020 07:32PM
8
May 06, 2020 08:51AM
2
May 06, 2020 09:35AM
4
May 06, 2020 03:21PM
Share
New Message
Please login to post a reply